Essential Thrombocythemia (ET) is uncommon blood cancer, which is one of the classic myeloproliferative neoplasms. It is a condition in which the bone marrow produces too many platelets. Patients with Essential Thrombocythemia have increased numbers of platelets. Red blood cell numbers are usually normal in ET, while white blood cell numbers are normal or slightly raised in Essential Thrombocythemia.&nbsp;&nbsp;
&nbsp;
Essential Thrombocythemia Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Essential Thrombocythemia in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Prevalent Cases of Essential Thrombocythemia</li>
<li>Prevalence of Essential Thrombocythemia&nbsp;Based on Symptoms</li>
<li>Gender-specific Prevalence of Essential Thrombocythemia</li>
<li>Age-specific Prevalence of Essential Thrombocythemia</li>
<li>Prevalence of Essential Thrombocythemia&nbsp;Cases Based on Risk</li>
<li>Gene Mutation specific Prevalence of Essential Thrombocythemia</li>
</ul>
&nbsp;
Essential Thrombocythemia Epidemiology&nbsp;
<ul>
<li>The total prevalent population of Essential Thrombocythemia&nbsp;in 7MM in 2017 was 232,688&nbsp;&nbsp;</li>
<li>The prevalent population of Essential Thrombocythemia in the United States was 142,635 in 2017</li>
<li>The age group of 60-80 years accounted for the highest cases of Essential Thrombocythemia&nbsp;in the United States&nbsp;&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/essential-thrombocythemia-et-market-insights" target="_blank" rel="noopener noreferrer">Essential Thrombocythemia Market</a>
The market size of Essential Thrombocythemia in 7MM in 2017 was USD 616.05 million&nbsp;&nbsp;
&nbsp;
Essential Thrombocythemia Market Drivers
<ul>
<li>Rich emerging pipeline</li>
<li>Updated diagnostic criteria</li>
<li>Reach of bone marrow biopsy</li>
<li>Research and Development</li>
</ul>
&nbsp;
Essential Thrombocythemia Market Barriers
<ul>
<li>Low disease understanding</li>
<li>Generics of approved drugs</li>
<li>Complications with the available treatment options</li>
<li>Lack of disease awareness</li>
</ul>
&nbsp;
Essential Thrombocythemia Emerging Drugs
The emerging drugs of the Essential Thrombocythemia market are&nbsp;
<ul>
<li>Ropeginterferon alfa-2b (P1101)</li>
<li>Jakavi (ruxolitinib)</li>
<li>Bomedemstat (IMG-7289)</li>
<li>Gandotinib (LY2784544)</li>
<li>Imetelstat</li>
<li>Givinostat (ITF2357)</li>
<li>Anagrelide Controlled Release/GALE-401</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Essential Thrombocythemia Key Players
The key players in the Essential Thrombocythemia market are
<ul>
<li>PharmaEssentia</li>
<li>Novartis</li>
<li>Imago BioSciences</li>
<li>Eli Lilly and Company</li>
<li>Geron Corporation</li>
<li>Italfarmaco</li>
<li>Galena Biopharma</li>
</ul>
And many others.&nbsp;

Essential Thrombocythemia Market

Essential Thrombocythemia

Essential Thrombocythemia Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape. 